Table 5. Incremental cost^a per woman of Option B+^b relative to Option B^c over 5 years postpartum, by CD4+ cell count and breastfeeding status, for varying rates of decline in CD4+ cell count.

Breastfeeding status	CD4+ count 350–500 cells/µl				CD4+ count > 500 cells/µl
	Total cost Option B+	Total cost Option B	Incremental cost		Total cost Option B+	Total cost Option B	Incremental cost
Breastfeeding (12 months)
Rate of CD4+ cell decline
Averaged	2069	1814	255		2069	1261	808
Rapide	2069	1948	121		2069	1261	808
Slowf	–	1261	808		–	1261	808
ARV price
Doubled	2905	2330	575		2905	1428	1477
Halved	1650	1556	94		1650	1177	473
No breastfeeding
Rate of CD4+ cell decline
Averaged	2069	1915	154		2069	1059	1010
Rapidg	2069	1982	87		2069	1460	609
Slowh	–	1730	339		–	1059	1010
ARV price
Doubled	2905	2514	391		2905	1059	1846
Halved	1650	1615	35		1650	1059	591

ARV, antiretroviral.

^a All costs are given in 2011 United States dollars (US$).

^b Option B+ comprises a triple antiretroviral (ARV) regimen initiated during pregnancy and continued for life.

^c Option B comprises a maternal triple ARV regimen, typically consisting of the recommended first-line antiretroviral therapy, during pregnancy and throughout breastfeeding, in combination with 6 weeks of daily nevirapine for the infant, regardless of infant feeding method.

^d 3.9 cells/µl/month.

^e 4.9 cells/µl/month.

^f 1.5 cells/µl/month.

^g 6.0 cells/µl/month.

^h 2.7 cells/µl/month.

Sources: CD4+ cell count declines for breastfeeding and non-breastfeeding women were obtained from Otieno;¹⁸ the full price of ARVs was obtained from WHO GPRM.¹⁷